{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:26:04Z","timestamp":1792805164531,"version":"4.5.0"},"reference-count":114,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Quanzhou Municipal Science and Technology Program","award":["2016Z006"],"award-info":[{"award-number":["2016Z006"]}]},{"name":"Key Project on the Integration of Industry and University of Fujian Province","award":["2018Y4009"],"award-info":[{"award-number":["2018Y4009"]}]},{"name":"Subsidized Project for Cultivating Postgraduates\u2019 Innovative Ability in Scientific Research of Huaqiao University","award":["1601116007"],"award-info":[{"award-number":["1601116007"]}],"id":[{"id":"https:\/\/ror.org\/03frdh605","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy.<\/jats:p>","DOI":"10.3390\/ijms20020317","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T12:20:07Z","timestamp":1547468407000},"page":"317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy"],"prefix":"10.3390","volume":"20","author":[{"given":"Jianguang","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Diao","sequence":"additional","affiliation":[{"name":"School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2013-11-427781","article-title":"Human innate lymphoid cells","volume":"124","author":"Hazenberg","year":"2014","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2013.07.006","article-title":"Natural killer cell biology: An update and future directions","volume":"132","author":"Campbell","year":"2013","journal-title":"J. Allergy Clin. Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s41590-018-0163-6","article-title":"Natural killer cell specificity for viral infections","volume":"19","author":"Hammer","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","article-title":"Exploitation of natural killer cells for the treatment of acute leukemia","volume":"127","author":"Handgretinger","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.4049\/jimmunol.178.8.4947","article-title":"CD56brightCD16- Killer Ig-Like Receptor- NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation","volume":"178","author":"Romagnani","year":"2007","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","article-title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: A potential new link between adaptive and innate immunity","volume":"101","author":"Fehniger","year":"2003","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood-2014-04-569061","article-title":"Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells","volume":"124","author":"Romain","year":"2014","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbcan.2018.01.005","article-title":"Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell","volume":"1869","author":"Lin","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation","volume":"108","author":"Bozzano","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: Natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.4049\/jimmunol.162.12.6976","article-title":"Cutting edge: Expression of functional CD94\/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: A possible mechanism of tolerance during NK cell development","volume":"162","author":"Sivakumar","year":"1999","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/imm.12921","article-title":"Natural killer cell cytotoxicity and its regulation by inhibitory receptors","volume":"154","author":"Kumar","year":"2018","journal-title":"Immunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1126\/science.1071553","article-title":"The Fas Signaling Pathway: More Than a Paradigm","volume":"296","author":"Wajant","year":"2002","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1440-1711.1999.00837.x","article-title":"Cell death induced by the Fas\/Fas ligand pathway and its role in pathology","volume":"77","author":"Waring","year":"1999","journal-title":"Immunol. Cell Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.4049\/jimmunol.129.6.2831","article-title":"Cell surface phenotype of a cloned line of human natural killer cells","volume":"129","author":"Kornbluth","year":"1982","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"16963","DOI":"10.1073\/pnas.012681099","article-title":"Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity","volume":"99","author":"Barakonyi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.159.3.1200","article-title":"Involvement of protein tyrosine kinase p72syk and phosphatidylinositol 3-kinase in CD2-mediated granular exocytosis in the natural killer cell line, NK3.3","volume":"159","author":"Umehara","year":"1997","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0171-2985(89)80019-1","article-title":"Kinetics of cellular cytotoxicity mediated by a cloned human natural killer cell line","volume":"179","author":"Mahle","year":"1989","journal-title":"Immunobiology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","article-title":"TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells)","volume":"134","author":"Yodoi","year":"1985","journal-title":"J. Immunol."},{"key":"ref_28","first-page":"136","article-title":"Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT","volume":"6","author":"Yoneda","year":"1992","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1073\/pnas.0604236103","article-title":"CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","first-page":"406","article-title":"Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia","volume":"24","author":"Robertson","year":"1996","journal-title":"Exp. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1046\/j.1365-2141.1998.01029.x","article-title":"Establishment of an IL-2-dependent cell line derived from \u2018nasal-type\u2019 NK\/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus","volume":"103","author":"Kagami","year":"1998","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.V92.4.1374","article-title":"Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma\/leukemia associated with Epstein-Barr virus infection","volume":"92","author":"Tsuchiyama","year":"1998","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/sj.leu.2401769","article-title":"A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation","volume":"14","author":"Yagita","year":"2000","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.exphem.2005.06.024","article-title":"KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity","volume":"33","author":"Suck","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.V97.3.708","article-title":"Characterization of novel natural killer (NK)-cell and gammadelta T-cell lines established from primary lesions of nasal T\/NK-cell lymphomas associated with the Epstein-Barr virus","volume":"97","author":"Nagata","year":"2001","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0145-2126(03)00254-6","article-title":"A new human natural killer leukemia cell line, IMC-1. A complex chromosomal rearrangement defined by spectral karyotyping: Functional and cytogenetic characterization","volume":"28","author":"Chen","year":"2004","journal-title":"Leukemia Res."},{"key":"ref_37","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/106161299320316","article-title":"Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92","volume":"8","author":"Tam","year":"1999","journal-title":"J. Hematother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1182\/blood.V87.11.4913.bloodjournal87114913","article-title":"Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells","volume":"87","author":"Klingemann","year":"1996","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/0008-5472.CAN-03-1562","article-title":"Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells","volume":"64","author":"Isobe","year":"2004","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematother. Stem Cell. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jcyt.2017.07.008","article-title":"Phase 1 clinical trial of adoptive immunotherapy using \u201coff-the-shelf\u201d activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia","volume":"19","author":"Boyiadzis","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/15258160152509145","article-title":"Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92","volume":"10","author":"Tonn","year":"2001","journal-title":"J. Hematother. Stem Cell. Res."},{"key":"ref_48","first-page":"2859","article-title":"Antileukemia activity of a natural killer cell line against human leukemias","volume":"4","author":"Yan","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","article-title":"Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model","volume":"97","author":"Swift","year":"2012","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.exphem.2004.11.003","article-title":"Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells","volume":"33","author":"Konstantinidis","year":"2005","journal-title":"Exp. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14653240310001523","article-title":"Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy","volume":"5","author":"Tam","year":"2003","journal-title":"Cytotherapy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural Killer Cells for Immunotherapy\u2014Advantages of the NK-92 Cell Line over Blood NK Cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/imt.15.6","article-title":"CAR therapy for hematological cancers: Can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?","volume":"7","author":"Pegram","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"139r","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"224r","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2012.01.001","article-title":"Cancer immunotherapy: Are we there yet?","volume":"22","author":"Sredni","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"138r","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"(2018). FDA Approves Second CAR T-cell Therapy. Cancer Discov., 8, 5\u20136.","DOI":"10.1158\/2159-8290.CD-NB2017-155"},{"key":"ref_64","unstructured":"(2017). First-ever CAR T-cell therapy approved in U.S. Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","article-title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","volume":"127","author":"Jacoby","year":"2016","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-017-0519-7","article-title":"Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia","volume":"10","author":"Fan","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains","volume":"18","author":"Wang","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"a2485","DOI":"10.1101\/cshperspect.a002485","article-title":"ITAM-mediated signaling by the T-cell antigen receptor","volume":"2","author":"Love","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.semcancer.2006.07.005","article-title":"Tumor and viral recognition by natural killer cells receptors","volume":"16","author":"Arnon","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/cgt.2011.66","article-title":"Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor","volume":"19","author":"Tassev","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ni857","article-title":"NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation","volume":"3","author":"Gilfillan","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni0603-509","article-title":"The choices of a natural killer","volume":"4","author":"Trinchieri","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.molimm.2004.07.032","article-title":"2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells","volume":"42","author":"McNerney","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","article-title":"Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction","volume":"100","author":"Uherek","year":"2002","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2008.11.024","article-title":"Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells","volume":"33","author":"Boissel","year":"2009","journal-title":"Leukemia Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/neuonc\/nov318","article-title":"Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival","volume":"18","author":"Alkins","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/0008-5472.CAN-12-2609","article-title":"Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors","volume":"73","author":"Alkins","year":"2013","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00330-004-2526-7","article-title":"In vivo tracking of genetically engineered, anti-HER2\/neu directed natural killer cells to HER2\/neu positive mammary tumors with magnetic resonance imaging","volume":"15","author":"Meier","year":"2005","journal-title":"Eur. Radiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.nucmedbio.2008.02.006","article-title":"Tracking of [18F]FDG-labeled natural killer cells to HER2\/neu-positive tumors","volume":"35","author":"Meier","year":"2008","journal-title":"Nucl. Med. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Schonfeld","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_94","first-page":"95","article-title":"Specific growth inhibition of ErbB2expressing human breast cancer cells by genetically modified NK92 cells","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00262-015-1669-5","article-title":"Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma","volume":"64","author":"Seidel","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1582-4934.2011.01343.x","article-title":"NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin","volume":"16","author":"Esser","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.4049\/jimmunol.180.9.6392","article-title":"Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy","volume":"180","author":"Binyamin","year":"2008","journal-title":"J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Antonio, B., Su\u00f1e, G., Perez-Amill, L., Castella, M., and Urbano-Ispizua, A. (2017). Natural Killer Cells: Angels and Devils for Immunotherapy. Int J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091868"},{"key":"ref_100","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"Uherek","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2310\/7290.2009.00002","article-title":"Optical imaging of cellular immunotherapy against prostate cancer","volume":"8","author":"Tavri","year":"2009","journal-title":"Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mrm.22652","article-title":"Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging","volume":"65","author":"Meier","year":"2011","journal-title":"Magn. Reson. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/icb.2013.45","article-title":"Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody","volume":"91","author":"Zhang","year":"2013","journal-title":"Immunol. Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Genssler","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"djv375","DOI":"10.1093\/jnci\/djv375","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"56219","DOI":"10.18632\/oncotarget.11019","article-title":"Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fimmu.2015.00264","article-title":"Natural Killer Cell Immunotherapy: From Bench to Bedside","volume":"6","author":"Domogala","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3843","article-title":"Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene","volume":"35","author":"Chen","year":"2017","journal-title":"Nat. Biotechnol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:25:50Z","timestamp":1760185550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/2\/317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":114,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["ijms20020317"],"URL":"https:\/\/doi.org\/10.3390\/ijms20020317","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]}}}